Mainstay confirms its continued eligibility to the PEA-PME

DUBLIN--(BUSINESS WIRE)-- Regulatory News:

Mainstay Medical International plc (“Mainstay” or the “Company” listed on Euronext Paris: MSTY.PA and ESM of the Irish Stock Exchange: MSTY.IE) confirms today its continued eligibility to the PEA-PME (French equity savings plan for financing SMEs), in accordance with Decree n°.2014-283 applicable since 4 March 2014 and reflecting the application of Article 70 of 2014 finance law (n° 2013-1278 dated 29 December 2013) which set up the conditions of companies’ eligibility for the PEA-PME as follows:

- fewer than 5,000 employees, and

- annual revenues of less than €1.5 billion, or

- a balance-sheet total of less than €2.0 billion.

Mainstay Medical is an Irish medical device company with operations in Ireland, Australia, Germany and the United States. The Company is focused on bringing to market ReActiv8®, an implantable neurostimulation system to treat disabling Chronic Low Back Pain (“CLBP”).

- End -

About Mainstay

Mainstay is a medical device company focused on bringing to market an innovative implantable neurostimulation system, ReActiv8®, for people with disabling Chronic Low Back Pain (CLBP). The Company is headquartered in Dublin, Ireland. It has subsidiaries operating in Ireland, the United States, Australia and Germany, and its ordinary shares are admitted to trading on Euronext Paris (MSTY.PA) and the ESM of the Irish Stock Exchange (MSTY.IE).

About Chronic Low Back Pain

One of the recognised root causes of CLBP is impaired control by the nervous system of the muscles that dynamically stabilise the spine in the low back, and an unstable spine can lead to back pain. ReActiv8 is designed to electrically stimulate the nerves responsible for contracting these muscles and thereby help to restore muscle control and improve dynamic spine stability, allowing the body to recover from CLBP.

People with CLBP usually have a greatly reduced quality of life and score significantly higher on scales for pain, disability, depression, anxiety and sleep disorders. Their pain and disability can persist despite the best available medical treatments, and only a small percentage of cases result from an identified pathological condition or anatomical defect that may be correctable with spine surgery. Their ability to work or be productive is seriously affected by the condition and the resulting days lost from work, disability benefits and health resource utilisation put a significant burden on individuals, families, communities, industry and governments.

Further information can be found at www.mainstay-medical.com

CAUTION – in the United States, ReActiv8 is limited by federal law to investigational use only.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170123005875/en/

Mainstay Medical International plc
PR and IR Enquiries:
Consilium Strategic Communications (international strategic communications – business and trade media)
Chris Gardner, Mary-Jane Elliott, Jessica Hodgson, Hendrik Thys
Tel: +44 203 709 5700 / +44 7921 697 654
Email: [email protected]
or
FTI Consulting (for Ireland)
Jonathan Neilan
Tel: +353 1 663 3686
Email: [email protected]
or
NewCap (for France)
Julie Coulot
Tel: +33 1 44 71 20 40
Email: [email protected]
or
AndreasBohne.Com/Kötting Consulting (for Germany)
Andreas Bohne
Tel : +49 2102 1485368
Email: [email protected]
or
Investor Relations:
LifeSci Advisors, LLC
Brian Ritchie
Tel: + 1 (212) 915-2578
Email: [email protected]
or
ESM Advisers:
Davy
Fergal Meegan or Barry Murphy
Tel: +353 1 679 6363
Email: [email protected] or [email protected]

Source: Mainstay Medical International plc

You May Also Be Interested In

• Form 8.3 - DS Smith Plc
• Vranken-Pommery Monopole - Availability of the 2023 Reference Document (Including the Annual Financial Report)
• STAGWELL LAUNCHES LONDON HUB TO SUPPORT EUROPEAN EXPANSION